Cellectis SA (CLLS) Actualités

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: ...

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal...

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a...

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: ...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: ...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: ...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS...

Cellectis Reports Financial Results for First Quarter 2024

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]